External skin preparation containing rivastigmine and pharmaceutical salt thereof and preparation method of external skin preparation

Abstract

The invention discloses an external skin preparation containing rivastigmine and pharmaceutical salt thereof. According to the formula, a stabilizer and tocopherol are added at special proportions; meanwhile, a backing layer, which is made from a special material is adopted; the selected backing layer can obviously reduce influence to active ingredients of the preparation and effectively inhibit the increase in an impurity content of the preparation; meanwhile, on the basis of the combined actions of the adopted special stabilizer and backing layer, the active ingredients of the medicine (thepreparation) are further prevented from getting oxidized, so that the generation of oxidation impurities is relieved; therefore, the external rivastigmine skin preparation provided by the invention ishigher in stability and longer in period of validity.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to an external skin preparation of rivastigmine and a medicinal salt thereof for treating senile dementia symptoms and a preparation method thereof. Background technique [0002] At present, my country has entered an aging society, and Alzheimer's disease has become a disease that affects the lives and health of the people, especially the elderly. The current treatment methods cannot cure or even prevent the occurrence of Alzheimer's disease. The clinical drugs that can slow down the development of this disease include antioxidants, monoamine oxidase inhibitors, anti-inflammatory drugs and cholinease inhibitors, as well as biological agents that are still in the experimental stage. Engineered drugs such as brain nerve prosthetics. Cholinesterase inhibitors are currently internationally recognized and highly evaluated drugs for improving symptoms of Alzheimer's dementia. T...

AI Technical Summary

Problems solved by technology

In 2000, Novartis imported rivastigmine capsules for clinical application in my country. In 2007, rivastigmine patches were launched. The disadvantage of oral preparations is that it needs to be taken twice a day, and the gastrointestinal side effects are serious, so it is more convenient to develop and use , drugs with fewer adverse reactions have become an inevitable

It can be seen from the existing literature that there is no report on how to prevent the oxidation of the raw material drug in the rivastigmine patch

Images